GHK-Cu vs MOTS-c

GHK-Cu and MOTS-c are research peptides studied across multiple applications, particularly in anti-aging research. GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) first identified in human plasma in 1973, with levels declining significantly with age. It has a long history of use in dermatological studies for wound healing and collagen synthesis. In contrast, MOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in 2015, acting primarily as a metabolic regulator via AMPK activation. While both are explored for anti-aging, GHK-Cu focuses on skin regeneration and tissue repair, whereas MOTS-c targets metabolic health and exercise mimetic effects. This comparison examines their mechanisms, evidence bases, dosing protocols, and safety profiles to elucidate key differences and overlaps.

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) that plays a pivotal role in various biological processes. Discovered by Dr. Loren Pickart in 1973, GHK-Cu levels in human plasma are approximately 200 ng/mL at age 20 but decrease to around 80 ng/mL by age 60, suggesting a potential link to age-related decline in skin health. Research highlights its capacity to enhance wound healing, promote collagen synthesis, and modulate gene expression, with numerous studies supporting its efficacy in dermatological applications. The molecular weight of GHK-Cu is about 340 g/mol when complexed with copper, and its formula is C14H24N6O4Cu. Key findings indicate that GHK-Cu can improve skin firmness and elasticity, reduce fine lines and wrinkles, and accelerate tissue repair, making it a valuable candidate for anti-aging interventions.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene (MT-RNR1), first identified by Lee et al. in 2015. This peptide functions primarily as a metabolic regulator, with studies demonstrating its ability to activate AMPK, a critical energy sensor in cells. In preclinical models, particularly in mice, MOTS-c has shown promise in preventing diet-induced obesity and insulin resistance, as well as enhancing exercise capacity—evidenced by older mice running twice as long on treadmill tests compared to controls. Additionally, a modified analog of MOTS-c, known as CB4211, demonstrated good tolerability in a Phase 1 human trial, although no clinical trials have yet been conducted on native MOTS-c. The emerging evidence suggests that MOTS-c may improve insulin sensitivity and glucose metabolism while exhibiting anti-obesity effects, positioning it as a novel target in metabolic health research.

GHK-Cu and MOTS-c, while both studied for their anti-aging properties, have distinct research applications reflecting their unique mechanisms of action. GHK-Cu is primarily focused on enhancing skin health and facilitating wound healing, leveraging its role in collagen synthesis and extracellular matrix remodeling. This peptide has been extensively used in dermatological studies and cosmetic formulations, highlighting its potential in skin regeneration. In contrast, MOTS-c is predominantly investigated for its effects on metabolic health, including improving insulin sensitivity and glucose metabolism, as well as its potential to mimic exercise effects. This focus on metabolic regulation underscores the importance of cellular energy homeostasis in combating age-related decline. Researchers may consider these complementary pathways when designing studies aimed at addressing various aspects of aging.

GHK-Cu is recognized for its excellent safety profile, with minimal side effects reported over decades of clinical and cosmetic use (PMID: 29986520). Topical applications are generally well tolerated, with mild skin irritation being a rare occurrence, typically confined to sensitive skin types. Injectable formulations may result in mild reactions at the injection site, as well as transient symptoms such as lightheadedness or nausea; however, these effects can often be mitigated by rotating injection sites. In contrast, the safety profile of MOTS-c remains less established, as no completed human trials have been conducted on the native peptide. Preclinical studies in animal models have not reported adverse effects, suggesting a favorable tolerability profile. Nonetheless, the lack of human data means that safety cannot be guaranteed. The modified analog CB4211 has shown good tolerability in Phase 1 trials, but this does not directly translate to the safety of native MOTS-c.